Sareum Holdings plc (LON:SAR – Get Free Report)’s stock price traded up 1.9% during mid-day trading on Monday . The company traded as high as GBX 27 ($0.34) and last traded at GBX 27 ($0.34). 264,022 shares traded hands during mid-day trading, a decline of 61% from the average session volume of 674,550 shares. The stock had previously closed at GBX 26.50 ($0.33).
Sareum Trading Up 1.2 %
The company has a market capitalization of £29.49 million, a price-to-earnings ratio of -466.50 and a beta of -1.08. The company’s 50 day simple moving average is GBX 26.23 and its 200-day simple moving average is GBX 30.35.
About Sareum
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases.
Read More
- Five stocks we like better than Sareum
- Stock Splits, Do They Really Impact Investors?
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- What is an Earnings Surprise?
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- 3 Small Caps With Big Return Potential
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
